Results from a phase Ib study of trastuzumab emtansine (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab.

被引：0
|
作者：
Modi, Shanu
Elias, Anthony D.
LoRusso, Patricia
Samant, Meghna
Guardino, Ellie
Althaus, Betsy
Krop, Ian E.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Univ Colorado, Ctr Canc, Aurora, CO USA
[3] Karmanos Canc Inst, Detroit, MI USA
[4] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[5] Genentech Inc, San Francisco, CA 94080 USA
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
528
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Trastuzumab emtansine (T-DM1) in previously treated HER2-positive metastatic breast cancer (MBC): Results from an expanded access study
    Yardley, Denise Aysel
    Krop, Ian E.
    LoRusso, Patricia
    Robert, Nicholas J.
    Mayer, Musa
    Abidoye, Oyewale O.
    Lai, Catherine
    Yoo, Bongin
    Perez, Edith A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [2] Efficacy of trastuzumab emtansine (T-DM1) in patients (pts) with HER2+metastatic breast cancer (MBC) previously treated with pertuzumab (P).
    Urruticoechea, Ander
    Im, Seock-Ah
    Munoz, Montserrat
    Baselga, Jose
    Yardley, Denise A.
    Heeson, Sarah
    Jones, Sarah
    Knott, Adam
    Douthwaite, Hannah
    Crnjevic, Tanja Badovinac
    Swain, Sandra M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
    Ian E. Krop
    Shanu Modi
    Patricia M. LoRusso
    Mark Pegram
    Ellie Guardino
    Betsy Althaus
    Dan Lu
    Alexander Strasak
    Anthony Elias
    Breast Cancer Research, 18
  • [4] Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
    Krop, Ian E.
    Modi, Shanu
    LoRusso, Patricia M.
    Pegram, Mark
    Guardino, Ellie
    Althaus, Betsy
    Lu, Dan
    Strasak, Alexander
    Elias, Anthony
    BREAST CANCER RESEARCH, 2016, 18
  • [5] Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
    Boyraz, Baris
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Babacan, Taner
    Roach, Emir C.
    Kizilarslanoglu, Muhammet C.
    Petekkaya, Ibrahim
    Altundag, Kadri
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (04) : 405 - 414
  • [6] A Dose-Escalation Study of Trastuzumab-DM1 (T-DM1), Paclitaxel (T), and Pertuzumab (P) in Patients with HER2-Positive, Locally Advanced or Metastatic Breast Cancer (MBC) Previously Treated with a Trastuzumab-Containing Regimen
    Krop, I. E.
    Modi, S.
    Elias, A.
    LoRusso, P.
    Choi, Y. J.
    Lu, M.
    CANCER RESEARCH, 2010, 70
  • [7] Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study
    Martin, M.
    Fumoleau, P.
    Dewar, J. A.
    Albanell, J.
    Limentani, S. A.
    Campone, M.
    Chang, J. C.
    Patre, M.
    Strasak, A.
    de Haas, S. L.
    Xu, J.
    Garcia-Saenz, J. A.
    ANNALS OF ONCOLOGY, 2016, 27 (07) : 1249 - 1256
  • [8] Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
    Lu, Dan
    Burris, Howard A., III
    Wang, Bei
    Dees, E. Claire
    Cortes, Javier
    Joshi, Amita
    Gupta, Manish
    Yi, Joo-Hee
    Chu, Yu-Waye
    Shih, Ted
    Fang, Liang
    Girish, Sandhya
    CURRENT DRUG METABOLISM, 2012, 13 (07) : 911 - 922
  • [9] Trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer
    Thibault, C.
    ONCOLOGIE, 2013, 15 (02) : 126 - 127
  • [10] Trastuzumab emtansine (T-DM1) for the treatment of HER2-positive breast cancer
    Sliwkowski, Mark X.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
12345